Slideset
View More
In this downloadable slideset, review criteria for initiating HBV therapy, opportunities to broaden candidacy for treatment, and the potential biologic consequences of untreated infection.
Ira M. Jacobson, MD
Released: June 21, 2019
Hear expert insights on the evidence for treating patients with immune-tolerant CHB and what ALT threshold should define HBV treatment candidacy in this on-demand audio commentary.
Ira M. Jacobson, MD
Released: September 5, 2019
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.